Title : Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib.

Pub. Date : 2011 Sep

PMID : 21251937






6 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
3 BACKGROUND & AIMS: Nilotinib is a novel tyrosine kinase inhibitor of Bcr-Abl and other kinases. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
4 Furthermore, PDGF- and TGFbeta-activated phosphorylated form(s) of Abl in human HSCs were inhibited by Nilotinib. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
5 We also observed reduced expression of phosphorylated ERK, Akt, and Abl in the Nilotinib-treated CCl(4) and BDL livers. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
6 CONCLUSIONS: These studies uncover a novel role of Bcr-Abl activity in treatment of liver fibrosis through multiple mechanisms and indicate that Nilotinib represents a potentially effective antifibrotic agent. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens